Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

L. Du, C. Yau, L. Brown-Swigart, R. Gould, G. Krings, G. L. Hirst, I. Bedrosian, R. M. Layman, J. M. Carter, M. Klein, S. Venters, S. Shad, M. van der Noordaa, A. J. Chien, T. Haddad, C. Isaacs, L. Pusztai, K. Albain, R. Nanda, D. TripathyM. C. Liu, J. Boughey, R. Schwab, N. Hylton, A. DeMichele, J. Perlmutter, D. Yee, D. Berry, L. van't Veer, V. Valero, L. J. Esserman, W. F. Symmans

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences